ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
97 252,50
-0,52%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mainz BioMed NV (MYNZ)

  7. Mainz BioMed NV (MYNZ) Actualités

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MYNZ
DateHeureSourceTitreSymboleSociété
19/12/202414h01GlobeNewswire Inc.Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestNASDAQ:MYNZMainz BioMed NV
16/12/202423h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
16/12/202423h00GlobeNewswire Inc.Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingNASDAQ:MYNZMainz BioMed NV
16/12/202414h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MYNZMainz BioMed NV
13/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MYNZMainz BioMed NV
13/12/202402h00GlobeNewswire Inc.Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesNASDAQ:MYNZMainz BioMed NV
11/12/202415h22InvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:MYNZMainz BioMed NV
11/12/202414h00Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
29/11/202414h45GlobeNewswire Inc.Mainz Biomed Announces Stock SplitNASDAQ:MYNZMainz BioMed NV
12/11/202415h00GlobeNewswire Inc.Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsNASDAQ:MYNZMainz BioMed NV
05/11/202414h00Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:MYNZMainz BioMed NV
21/10/202414h01GlobeNewswire Inc.Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
08/10/202414h01GlobeNewswire Inc.Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionNASDAQ:MYNZMainz BioMed NV
01/10/202414h01GlobeNewswire Inc.Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025NASDAQ:MYNZMainz BioMed NV
18/09/202414h01GlobeNewswire Inc.Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand AmbassadorNASDAQ:MYNZMainz BioMed NV
04/09/202410h01GlobeNewswire Inc.Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlertNASDAQ:MYNZMainz BioMed NV
25/07/202414h01GlobeNewswire Inc.Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User ConvenienceNASDAQ:MYNZMainz BioMed NV
09/07/202415h30AllPennyStocks.comMicro Cap Bid Up Following FDA Submission AnnouncementNASDAQ:MYNZMainz BioMed NV
09/07/202409h01GlobeNewswire Inc.Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening TestNASDAQ:MYNZMainz BioMed NV
02/07/202414h01GlobeNewswire Inc.Mainz Biomed Provides Half Year 2024 Corporate UpdateNASDAQ:MYNZMainz BioMed NV
03/06/202414h01GlobeNewswire Inc.Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024NASDAQ:MYNZMainz BioMed NV
31/05/202423h01GlobeNewswire Inc.Mainz Biomed Reports Results of 2024 Annual General MeetingNASDAQ:MYNZMainz BioMed NV
28/05/202414h01GlobeNewswire Inc.Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual MeetingNASDAQ:MYNZMainz BioMed NV
20/05/202414h01GlobeNewswire Inc.Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA TrialNASDAQ:MYNZMainz BioMed NV
10/05/202423h20Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]NASDAQ:MYNZMainz BioMed NV
07/05/202414h01GlobeNewswire Inc.Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.NASDAQ:MYNZMainz BioMed NV
25/04/202415h29GlobeNewswire Inc.Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer DiagnosticNASDAQ:MYNZMainz BioMed NV
09/04/202414h01GlobeNewswire Inc.Mainz Biomed Reports Full Year 2023 Financial ResultsNASDAQ:MYNZMainz BioMed NV
19/03/202413h01GlobeNewswire Inc.Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer TreatmentNASDAQ:MYNZMainz BioMed NV
18/03/202413h01GlobeNewswire Inc.Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic OptionsNASDAQ:MYNZMainz BioMed NV
 Showing the most relevant articles for your search:NASDAQ:MYNZ

Dernières Valeurs Consultées

COIN
SOLUSD
Solana
EU
PX1
CAC 40
EU
DG
Vinci
NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
COIN
DOGEUSD
Dogecoin
NYSE
DIS
Walt Disney
EU
HO
Thales
NYSE
NKE
Nike
SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés